MedTrace Logo

Sirolimus Eluting Stenting in Acute Myocardial Infarction

NCT00288210 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2006-02-10

No results posted yet for this study

Summary

The incidence of stent restenosis in the setting of primary angioplasty is particularly high, reaching a rate of 27% In the last years the introduction of drug-eluting stents has drastically reduced the incidence of restenosis in patients not requiring urgent revascularization. Whether drug-eluting stenting might constitute the new optimal therapy for patients with an acute myocardial infarction is unknown. To be able to answer this question, we designed a randomized trial in which patients with an acute myocardial infarction eligible for treatment with primary angioplasty and abciximab were randomized to receive either a rapamicine-eluting stent or a conventional bare stent.

Conditions

Interventions

PROCEDURE

Primary angioplasty in acute myocardial infarction

Sponsors & Collaborators

  • San Camillo Hospital, Rome

    lead OTHER

Principal Investigators

  • Roberto Violini, MD · Cardiologia Interventistica Ospedale San Camillo Roma

  • Maurizio Menichelli, MD · Cardiologia Interventistica Ospedale San Camillo Roma

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-03-31
Completion
2006-03-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00288210 on ClinicalTrials.gov